Outcome of gastric cancer patients after successful gastrectomy

The effect of the location of disease recurrence after curative (R0) gastrectomy on patient survival has not been elucidated. The authors hypothesized that the location of recurrence would have a significant influence on survival.

[1]  S. Sohn,et al.  Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer , 2006, British Journal of Cancer.

[2]  J. Roh,et al.  A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer , 2006, Oncology.

[3]  S. Park,et al.  Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil , 2006, Anti-cancer drugs.

[4]  L. Mariani,et al.  Pathological features as predictors of recurrence after radical resection of gastric cancer , 2006, The British journal of surgery.

[5]  J. Ajani,et al.  Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jeffrey W. Clark,et al.  A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma , 2005, Digestive Diseases and Sciences.

[7]  J. Ajani Evolving chemotherapy for advanced gastric cancer. , 2005, The oncologist.

[8]  Marco Lorenzi,et al.  Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer. , 2005, Hepato-Gastroenterology.

[9]  J. Ajani,et al.  Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Y. Nimura,et al.  Survival after surgical treatment of early gastric cancer, surgical techniques, and long-term survival , 2005, Langenbeck's Archives of Surgery.

[11]  G. Torre,et al.  Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2‐gastrectomy , 2005, Journal of surgical oncology.

[12]  Dimitrios H Roukos,et al.  Perspectives in the treatment of gastric cancer , 2005, Nature Clinical Practice Oncology.

[13]  J. Macdonald Treatment of localized gastric cancer. , 2004, Seminars in oncology.

[14]  M. Akmansu,et al.  Results of chemoirradiation after curative resection of locally advanced gastric cancer , 2004, International journal of clinical practice.

[15]  Masahiko Watanabe,et al.  Survival after surgical treatment of early gastric cancer: surgical techniques and long-term survival , 2004, Langenbeck's Archives of Surgery.

[16]  J. Feinglass,et al.  Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. , 2003, Surgery.

[17]  Aller,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.

[18]  J. Ajani,et al.  CPT‐11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma , 2002, Cancer.

[19]  S. Weeden,et al.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of MRC randomized surgical trial , 2001 .

[20]  L. Oñate-Ocaña,et al.  Survival benefit of D2 lymphadenectomy in patients with gastric adenocarcinoma , 2000, Annals of Surgical Oncology.

[21]  P. Fayers,et al.  Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial , 1999, British Journal of Cancer.

[22]  S. Kim,et al.  Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer , 1998, Gastric Cancer.

[23]  S. Groshen,et al.  Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy , 1997, Cancer.

[24]  J. Chmiel,et al.  Cancer of the stomach. A patient care study by the American College of Surgeons. , 1993, Annals of surgery.

[25]  J. Ajani,et al.  Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy , 1991, Cancer.

[26]  H. Kalofonos,et al.  Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study , 2005, Gastric Cancer.

[27]  M. Huguier,et al.  [Extended lymph-node dissection for gastric cancer]. , 1999, Chirurgie; memoires de l'Academie de chirurgie.

[28]  S. Kim,et al.  Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer , 1998 .